← Eichor
Condition: Nf1 Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nf1 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT04166409PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839RASopathy Biorepository
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT04395495
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.